For research use only
| Cat No. | ABC-X0023C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Fibroblast |
| Species | Human |
| Host Cell | NIH/3T3 |
| Source Organ | Embryo |
| Disease | Normal |
| Storage | Liquid Nitrogen |
The FGFR3 (V555M) NIH/3T3 cell line is an ideal platform for studying FGFR3 activating mutations, facilitating the development and validation.
Human FGFR3 (V555M) NIH/3T3 Cell Line is a genetically engineered model derived from selected murine NIH/3T3 parental cell line based on customers’ requirement. FGFR3 (V555M) NIH/3T3 mutant cell line is generated by stable integration of exogenous human FGFR3 gene harboring the V555M point mutation into NIH/3T3 host cells using our optimized transduction of lentiviral vectors.
Target
FGFR3 encodes fibroblast growth factor receptor 3, a transmembrane tyrosine kinase involved in cell differentiation, proliferation, and survival. The V555M mutation occurs in the kinase domain and has been reported as an activating mutation associated with oncogenic transformation. FGFR3 alterations are implicated in multiple malignancies including bladder cancer, multiple myeloma, and cervical cancer. AcceGen offers generation of stable overexpression and mutation-specific cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0023C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Fibroblast |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO₂ |
| Source Organ | Embryo |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | NIH/3T3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The FGFR3 (V555M) NIH/3T3 Cell Line serves as a powerful tool to investigate FGFR3-mediated signaling and oncogenesis. This model enables mechanistic studies of constitutive kinase activation, MAPK/ERK pathway upregulation, and response to FGFR-targeted inhibitors. It is utilized for preclinical drug screening and validation of precision oncology therapeutics.